<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201201049560N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-15</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The comparative  of Poulk vaginal gel and metronidazole vaginal gel effect on treatment of bacterial vaginosis</public_title>
      <acronym></acronym>
      <scientific_title>The comparative  of Poulk vaginal gel and metronidazole vaginal gel effect on treatment of bacterial vaginosis in Vaginosis patients : A Double Blind Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>112</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52708</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: The patients will be assigned to two groups of Poulk gel (50 g, 5%) and Metranidazole gel (50g 75%) and written consent will be obtained from patients to participate in this study. In the first group, 75% of metranidazole gel will be given daily in an intravaginal applicator daily for 7 days and in second group, 5% of poulk gel will be given daily in applicator for 7 days. Patients will be advised to stay in the supine position for at least 30 minutes after  taking the drug. Patients will also be given the Larson sexual satisfaction questionnaire and FSFI sexual function questionnaire, Randomization description: The allocation of individuals in the groups will be done in a random block with 19 blocks  of 6 by allocation 1:1 in the two groups.In this way, the letters A and B will be assigned to each group, and  randomized list provide by statistician. In this study,  almost all possible cases of 19 blocks of 6 and assigning numbers to each of them are prepared randomly by a statistician using the WWW.Randomizer.org site. Poulk vaginl gel and metronidazole gel will be placed in the closed envelopes according to the randomized list and different codes by the person outside the study then assigned to any patient that enter the study. Poulk vaginal gel and metronidazole gel are identical in appearance, packaging, color, Blinding description: In this study, Researcher and participants will be unaware of the type of treatment they receive Poulk vaginal gel or metronidazole gel and pharmacist will fill the tubes. For the purpose of blinding, Poulk vaginal gel and metronidazole gel tubes will be placed in closed envelopes according to the randomized list and different codes will be assigned to any patient that enters the study by a person outside the study. Poulk vaginal gel or metronidazole gel tubes are identical in appearance, packaging and color. The patients will be reminded that their placement in each of the groups will be random.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Bacterial Vaginosis.</hc_freetext>
      <i_freetext>Intervention 1: 5% vaginal gel, 50 g, 7 days, 1 applicator 5 g every night while sleeping inside the vagina. Extraction(Extraction of plant leaves using soaking method and using 80% aqueous solutions) and making of gel is done in school of pharmacy in Ahvaz Medical Science . Intervention 2: Control group: metronidazole vaginal  gel(an applicator 75%) once a day for 7 days. Metranidazole gel made by Behsan Daroo comopany, Which is placed in tubes similar to poulk vaginal gel in school of pharmacy in Ahvaz Medical Science.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is not more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mina Iravani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University of Medical Sciences,Golestan Blvd, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3373 8331</telephone>
        <email>minairavani2004@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mina iravani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz,Golestan Blvd, University of Medical Sciences, Ahvaz,</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3373 8331</telephone>
        <email>minairavani@yahoo.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>willingness to cooperate
positive Whiff test
signs of bacterial vaginosis in examination
Positive cluecell</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Multi partner
Stricken to specific diseases like liver diseases ,kidney diseases and central chords system diseases ,blood dyscrasi ,diabetes ,impair of safety system
Having abnormal uterus bleeding
Frequently vulvovaginits
pregnancy
Mensturation
Lactating
Use of vaginal douches frequently, consuming remedy for treatment in 3 recent months
Consumig alcohol and anti coagulation remedies and recent consuming anti-parasite remedy, anti-biotic, weakening remedy of safety system and vaginalis remedy
President of allergy in using metronidazol tablet
consuming remedy for treatment in 3 recent months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N76.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other specified inflammation of vagina and vulva</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>5% vaginal gel, 50 g, 7 days, 1 applicator 5 g every night while sleeping inside the vagina. Extraction(Extraction of plant leaves using soaking method and using 80% aqueous solutions) and making of gel is done in school of pharmacy in Ahvaz Medical Science .</i_keyword>
      <i_keyword>Control group: metronidazole vaginal  gel(an applicator 75%) once a day for 7 days. Metranidazole gel made by Behsan Daroo comopany, Which is placed in tubes similar to poulk vaginal gel in school of pharmacy in Ahvaz Medical Science.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bacterial Vaginosis. Timepoint: Before treatment and after treatment. Method of measurement: Based on the criteria of Amsell (Evaluation of vaginal discharge in terms of odor, color and presence of key cells with the emphasis on emphasis)  and Nugent.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Vaginal discharge. Timepoint: 14-28 days after treatment. Method of measurement: Observation.</sec_outcome>
      <sec_outcome>The acidity of vagina. Timepoint: 14-28 days after treatment. Method of measurement: PH strip.</sec_outcome>
      <sec_outcome>Whiff test. Timepoint: 14-28 days after treatment. Method of measurement: Potassium hydroxide solution 10%.</sec_outcome>
      <sec_outcome>Clue cells. Timepoint: 14-28 days after treatment. Method of measurement: Evaluation of clue cells on the wet lam.</sec_outcome>
      <sec_outcome>Sexual Fanction score. Timepoint: Before and 14 days after treatment. Method of measurement: Rosen Sexual Function Questionnaire.</sec_outcome>
      <sec_outcome>Sexual Satisfaction score. Timepoint: Before and 14 days after treatment. Method of measurement: Larson Sexual Satisfaction Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-22</approval_date>
        <contact_name>Ethics committee of Ahvaz University of Medical Sciences</contact_name>
        <contact_address>Ahvaz, Expressway, Golestan University of Medical Sciences, Ahvaz, Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
